CinnaGen Reports Results Of ReciGen For COVID-19
Interferon Beta-1a In Combination Therapy For COVID-19 Pneumonia
CinnaGen has revealed clinical trial results suggesting that its ReciGen interferon beta-1a product in combination with concomitant antiviral therapy can be “a new safe and effective” treatment option for COVID-19 patients, “critical for the expected second wave of the pandemic.”
